Second-line chemotherapy in head and neck cancer: What should we expect?

Expert Review of Anticancer Therapy

Volumn 9, Issue 3, 2009, Pages 269-273

  Büntzel, Jens ^a   Micke, Oliver ^b  

^a Suedharz Krankenhaus Nordhausen gGmbH   (Germany)

^b FRANZISKUS HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; INTERFERON; KI 67 ANTIGEN; LAPATINIB; METHOTREXATE; MITOMYCIN; PACLITAXEL; PANITUMUMAB; PLATINUM COMPLEX; PLATINUM DERIVATIVE; PROTEIN P53; PROTEIN TYROSINE KINASE; RETINOIC ACID; TAXANE DERIVATIVE; TROFOSFAMIDE; UNCLASSIFIED DRUG; ZALUTUMUMAB;

ADVANCED CANCER; ANAPHYLACTIC SHOCK; ANEMIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOPENIA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SCREENING; DRUG TARGETING; EDITORIAL; ENZYME INHIBITION; GENE EXPRESSION; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; LOADING DRUG DOSE; LUNG METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; NAUSEA; NEPHROTOXICITY; NEUROPATHY; OTOTOXICITY; OVERALL SURVIVAL; QUALITY OF LIFE; STOMATITIS; SURVIVAL TIME; TREATMENT INDICATION; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 65749099575     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.9.3.269     Document Type: Editorial

References (41)

1. Lester EP, Kinnealey A, Matz GJ. Sequential combination chemotherapy for advanced squamous cell carcinoma of the head and neck. Laryngoscope 89(12), 1921-1929 (1979).
2. Jahnke V. Experiences using combination chemotherapy with cis-platinum, bleomycin and methotrexate in the management of advanced squamous cell carcinomas of the head and neck. HNO 28, 405-408 (1980).
3. Wendt TG, Grabenbauer GG, Rodel CM et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J. Clin. Oncol. 16, 1318-1324 (1998).
4. Schäfer U, Schüller P, Micke O, Willich N. Simultaneous radiochemtherapy versus concomitant boost radiation for advanced inoperable head and neck cancer. Acta Oncologica 39, 523-528 (2000).
5. Mücke R, Blynow M, Ziegler PG et al. Concurrent radiotherapy and chemotherapy with carboplatin in patients with unresectable advanced head and neck tumors stages III and IV. Strahlenther. Onkol. 175, 213-217 (1999).
6. Kaplan MJ, Hahn SS, Johns ME, Stewart FE, Constable WC, Cantrell RW. Mitomycin and fluorouracil with concomitant radiotherapy in head and neck cancer. Arch. Otolaryngol. 111, 220-222 (1985).
7. Micke O, Matzkies F, Mucke R et al. Magnesium and zinc balance in cisplatinum-based radiochemotherapy in advanced head and neck cancer patients. Trace Elements Electrolytes 25, 234 (2008).
8. Büntzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, DeVries A. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled Phase III study. Int. J. Radiat. Oncol. Biol. Phys. 64, 684-691 (2006).
9. Büntzel J, Glatzel M, Bruns F, Kisters K, Micke O, Muecke R. Selenium supplementation in head and neck surgery. Trace Elements and Electrolytes 25, 221 (2008).
10. Forastiere AA. Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin. Oncol. 21(Suppl. 8), 49-52 (1994).
11. Benasso M, Numico G, Rosso R, Merlano M, Ricci I, Gentile A. Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study. Semin. Oncol. 24 (Suppl. 19), 46-50 (1997).
12. Büntzel J, Schuth J, Glatzel M. Doxorubicin in the palliative therapy of recurrent pretreated head and neck cancer. Proc. ASCO 21, 2556(a) (2002).
13. Stewart J, Lewanski C, Harrington K, Northcote D, Welbank H, Whittaker J. Comparison of pegylated liposomal doxorubcin (PLD) and pegylated liposomal cisplatinum (PLC) in patients with advanced head and neck squamous cell carcinoma (HNSCC). Proc. ASCO 19, 1672(a) (2000).
14. Zhang Q, Huang XE, Gao LL. A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors. Biomed. Pharmacother. DOI: 10.1016/j.biopha.2008.10.001 (2008) (Epub ahead of print).
15. Posner MR, Hershock DM, Blajman CR et al.; the TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med. 357, 1705-1715 (2007).
16. Pignon J, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355, 949-955 (2000).
17. Harari PM. Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice? J. Clin. Oncol. 15, 2050-2055 (1997).
18. Silverman S Jr, Gorsdy M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 53, 563-568 (1984).
19. Hong WK, Lippman SM, Itri LM et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N. Engl. J. Med. 323, 79.801 (1990).
20. Wan H, Oridate N, Lotan D, Hong WK, Lotan R. Overexpression of retinoic acid receptor β in head and neck squamous cell carcinoma cells increases their sensitivity to retinoid-induced suppression of squamous differentiation by retinoids. Cancer Res. 59, 3518-3526 (1999).
21. Mertens R, Granzen B, Lassay L et al. Treatment of nasopharyngeal carcinoma in children and adolescents: definitive results of a multicenter study (NPC-91-GPOH). Cancer 104, 1083-1089 (2005).
22. Padovan I, Brodarec I, Ikic D, Knezevic M, Soos E. Effect of interferon in therapy of skin and head and neck tumors. J. Cancer Res. Clin. Oncol. 100, 295-310 (1981).
23. Brigette BY, Poon TCW, To KF et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma - a prospective study. Head Neck 25, 864-872 (2003).
24. Brockstein B, Lacouture M, Agulnik M. The role of inhibitors of the epidermal growth factor in management of head and neck cancer. J. Natl Compr. Canc. Netw. 6(7), 696-706 (2008).
25. Kirby AM, A'Herm RP, D'Ambrosio C et al. Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer. Br. J. Cancer 94, 631-636 (2006).
26. Cohen EEW, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J. Clin. Oncol. 22, 1743-1752 (2004).
27. Montemurro F, Valabrega G, Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin. Biol. Ther. 2, 257-268 (2007).
28. Leon X, Hitt R, Constenla M et al. A retrospective analysis of the outcome of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) who are progressing while on a platinum-based palliative chemotherapy. Proc. ASCO 22, 2022 (2003).
29. Grose WE, Lehane DE, Dixon DO, Fletcher WS, Stuckey WJ. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest Oncology Group Study. Cancer Treat. Rep. 69, 577-581 (1985).
30. Ranieri G, Grammatica L, Patruno R et al. A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. J. Cell Mol. Med. 11, 362-368 (2007).
31. Airoldi M, Cortesina G, Giordano C, Pedani F, Bumma C. Ifosfamide in the treatment of head and neck cancer. Oncology 65(Suppl. 2), 37-43 (2003).
32. Al-Sarraf M. Treatment of locally advanced head and neck cancer: historical and critical review. Cancer Control 9, 387-399 (2002).
33. Volling P, Schröder M, Rauschning W, Achterrath W, Stennert E. Carboplatin - the better platinum in head and neck cancer? Arch. Otolaryngol. Head Neck Surg. 115(6), 695-698 (1989).
34. Jacobs C, Lyman G, Velez-Garcia E et al. A Phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. 10, 257-263 (1992).
35. Gibson MK, Li Y, Murphy B et al. Randomized Phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (e1395): an intergroup trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 23, 3562-3567 (2005).
36. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359, 1116-1127 (2008).
37. Guntinas-Lichius O, Tanvetyanon T, Vermorken JB. Cetuximab in head and neck cancer. N. Engl. J. Med. 359, 2725-2726 (2008).
38. Büntzel J, deVries A, Micke O. Experience with cetuximab plus paclitaxel/carboplatinum in primary platinum-resistant recurrent head and neck cancer, J. Clin. Oncol. 25, 6077(a) (2007).
39. Specenier P, Vermorken JB. The role of cetuximab in the treatment of head and neck cancer. BJMO 2, 161-167 (2008).
40. O'Neil BH, Allen R, Spigel DR et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J. Clin. Oncol. 25, 3644-3648 (2007).
41. Specenier P, Vermorken JB. Targeted therapies in head and neck cancer. Target. Oncol. 2(2), 73-88 (2007).